8-K: Black Diamond Therapeutics Holds Annual Meeting, Elects Directors

Black Diamond Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Summary

• Black Diamond Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026, in a virtual format.
• The meeting confirmed the election of Shannon Campbell and Kapil Dhingra as Class III directors, each to serve a three-year term.
• PricewaterhouseCoopers LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders approved, on an advisory basis, the compensation of the company's named executive officers.
• A majority of stockholders also voted in favor of holding future advisory votes on executive compensation annually.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms routine corporate governance matters and director appointments with expected outcomes, without significant surprises or new strategic information.

Positives

• Directors Shannon Campbell and Kapil Dhingra were elected to the Board.
• PricewaterhouseCoopers LLP was ratified as the independent auditor with overwhelming support (44,421,545 FOR votes).
• The compensation of named executive officers was approved on an advisory basis with significant support (35,071,684 FOR votes).
• Stockholders overwhelmingly supported annual advisory votes on executive compensation (30,446,520 votes for 1-YEAR frequency).

Negatives

• A significant number of shares were withheld for the election of Kapil Dhingra (22,503,924 shares).
• A notable portion of shares voted against the ratification of PricewaterhouseCoopers LLP (117,976 votes).
• A considerable number of shares voted against the compensation of named executive officers (1,243,945 votes).

Future Outlook

The company will hold future advisory votes on the compensation of its named executive officers on an annual basis.

Industry Context

StockSavvy.ai notes that the outcomes of annual meetings, including director elections and auditor ratification, are standard governance procedures for publicly traded companies. The advisory votes on executive compensation reflect ongoing trends in shareholder engagement and corporate accountability within the biotechnology sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmation of board composition and auditor provides stability. Advisory votes on compensation offer a mechanism for shareholder voice.
• Employees: Continued engagement with independent auditors and board oversight can indirectly support company stability.
• Creditors: Ratification of auditor and board elections can be seen as positive indicators of corporate governance, potentially reinforcing confidence.

Next Steps

• Shannon Campbell and Kapil Dhingra will serve as Class III directors until the 2029 annual meeting of stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Future advisory votes on executive compensation will be held annually.

Key Dates

Recommendation

This filing reports on routine annual meeting outcomes, including director elections and auditor ratification, with expected results. There is no new strategic information or significant financial data presented that would warrant a change in investment recommendation.

Keywords

Annual Meeting, Stockholder Vote, Director Election, Independent Auditor, Executive Compensation, Corporate Governance, Black Diamond Therapeutics